From the MD&A ...Dated March 25. 2021Pharmaceutical Collaborations Sernova now has multiple research collaboration agreements with global pharmaceutical companies. In this regard, Sernova is deploying its in-house cell therapy expertise and proprietary Cell Pouch technologies in combination with proprietary therapeutic cell assets designated by the pharmaceutical collaborators. The research collaborations follow the ongoing clinical success of our Cell Pouch technologies in diabetes and reflect the value and evolving recognition of our technologies and cell therapy platform. These important partnerships with leaders in the pharma industry build upon our business strategy to develop a portfolio of products to realize the full potential of Sernova’s regenerative medicine therapeutic platform by extending and broadening its application to new therapeutic areas and modalities. We believe partnering with multiple pharmaceutical companies not only will expand our therapeutic treatment potential but also provides a de-risked approach for Sernova as we develop our technologies and bring new therapies to patients with the goal to provide people with a functional cure for multiple chronic and rare diseases. The full MD&A is well worth reading and will provide many answers for those that take the time to enjoy reading it.
https://www.sernova.com/pdf/mda/2021Q1MDA.pdf